Asset Details
Do you wish to reserve the book?
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration
Do you wish to request the book?
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration
2023
Overview
Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration. The study was conducted June 2020 to March 2021. Eligibility required [greater than or equal to] 5 liters/minute of Oxygen to maintain peripheral oxygen saturation at [greater than or equal to] 93%, CRP > 70 mg/L, ferritin > 500 [mu]g/L and at least two points where one point was awarded for lymphocytes < 1x 10.sup.9 /L; D-dimer [greater than or equal to] 0.5 mg/L and; lactate dehydrogenase [greater than or equal to] 8 microkatal/L. Patients were randomly assigned 1:1:1 to receive either a single dose of tocilizumab (8 mg/kg) or anakinra 100 mg IV QID for seven days or UC alone. The primary outcome was time to recovery. Recruitment was ended prematurely when tocilizumab became part of usual care. Out of a planned 195 patients, 77 had been randomized, 27 to UC, 28 to anakinra and 22 to tocilizumab. Median time to recovery was 15, 15 and 11 days. Rate ratio for recovery for UC vs anakinra was 0.91, 0.47 to 1.78, 95% [CI], p = 0.8 and for UC vs tocilizumab 1.13, 0.55 to 2.30; p = 0.7. There were non-significant trends favoring tocilizumab (and to limited degree anakinra) vs UC for some secondary outcomes. Safety profiles did not differ significantly. Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).
Publisher
Public Library of Science
Subject
